摘要
目的观察在多囊卵巢综合征(PCOS)并胰岛素抵抗(IR)患者中,二甲双胍与吡格列酮联合应用及吡格列酮单独应用的临床疗效。方法对40例PCOS并IR患者进行前瞻性研究,并选取20例非PCOS不孕妇女为对照组。PCOS组根据BMI分为A、B两组,测定糖、脂代谢指标、生殖激素及C反应蛋白(CRP)等。A组20例(吡格列酮),B组20例(二甲双胍与吡格列酮)。经12周治疗后,再比较上述各指标的变化。结果 PCOS组治疗前胰岛素水平、生殖激素及CRP等均较对照组增高。2组患者治疗后胰岛素抵抗指数、甘油三脂及血清睾酮(T)等均较治疗前明显降低(P<0.05),B组BMI较治疗前明显下降(P<0.05)。应用协方差分析治疗后2组的各指标,2hINS、T在B组下降较A组更明显(P<0.05)。结论二甲双胍与吡格列酮联用治疗PCOS并IR,较单用吡格列酮更有效;慢性炎症反应可能参与PCOS的发生及发展过程,慢性炎症的发生可能是胰岛素敏感性降低的原因之一。
[ Objective ] To investigate the clinical theraputic effects of pioglitazone and pioglitazone plus met- formin in patients of polyeystie ovary syndrome （PCOS） with insulin resistance （IR）. [Methods] A prospective study involved total 40 PCOS patients as the examination group and 20 non-PCOS infertility patients as control. PCOS patients were divided into two groups according to BMI： group A （pioglitazone） and group B （pioglitazone plus met- formin）. Levels of sex hormone, C-reactive protein （CRP） were performed in all patients. After the end of 12-week therapy, above-mentioned parameters were re-evaluate- d. [Results] PCOS patients had significant increases in levels of blood insulin, sex hormone, CRP comparing with the control group; after the treatment, levels of insulin, IR, triglyceride, testosterone （T） decreased significantly than before in both groups （P 〈0.05）. BMI decreased significant- ly than before in group B （P 〈0.05）. The levels of BMI, 2bINS, T in group B were decreased significantly than group A by the covafianee analysis. [ Conclusion ] Pioglitazone plus metformin has better effects than pioglitazone mono- therapy; the chronic inflammation may participate in the pathogenesis of PCOS. Chronic inflammation may be one of the reasons to reducing insulin sensitivity.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2012年第27期72-76,共5页
China Journal of Modern Medicine
